Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. / Deacon, Carolyn F.
In: Expert Opinion on Investigational Drugs, Vol. 16, No. 4, 2007, p. 533-45.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
AU - Deacon, Carolyn F
N1 - Keywords: Adenosine Deaminase; Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Drugs, Investigational; Enzyme Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Triazoles
PY - 2007
Y1 - 2007
N2 - Sitagliptin is a once-daily, orally active, competitive and fully reversible inhibitor of dipeptidyl peptidase 4, the enzyme that is responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1. It is the first in this new class of antihyperglycaemic agents to gain regulatory approval for the treatment of Type 2 diabetes, both as a monotherapy and for use in combination with metformin or a thiazolidinedione. In clinical trials of < or = 1-year duration, sitagliptin improves glycaemic control by reducing both fasting and postprandial glucose concentrations, leading to clinically meaningful reductions in glycosylated haemoglobin levels. It is safe and well tolerated, with a side-effect profile that is similar to that of the placebo, a low incidence of hypoglycaemia and body weight neutrality. Further clinical experience with sitagliptin will reveal its long-term durability, safety and efficacy.
AB - Sitagliptin is a once-daily, orally active, competitive and fully reversible inhibitor of dipeptidyl peptidase 4, the enzyme that is responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1. It is the first in this new class of antihyperglycaemic agents to gain regulatory approval for the treatment of Type 2 diabetes, both as a monotherapy and for use in combination with metformin or a thiazolidinedione. In clinical trials of < or = 1-year duration, sitagliptin improves glycaemic control by reducing both fasting and postprandial glucose concentrations, leading to clinically meaningful reductions in glycosylated haemoglobin levels. It is safe and well tolerated, with a side-effect profile that is similar to that of the placebo, a low incidence of hypoglycaemia and body weight neutrality. Further clinical experience with sitagliptin will reveal its long-term durability, safety and efficacy.
U2 - 10.1517/13543784.16.4.533
DO - 10.1517/13543784.16.4.533
M3 - Journal article
C2 - 17371200
VL - 16
SP - 533
EP - 545
JO - Current Opinion in Investigational Drugs
JF - Current Opinion in Investigational Drugs
SN - 1354-3784
IS - 4
ER -
ID: 8416960